BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21627828)

  • 1. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change.
    Jones PW; Anderson JA; Calverley PM; Celli BR; Ferguson GT; Jenkins C; Yates JC; Vestbo J; Spencer MD;
    Respir Res; 2011 May; 12(1):71. PubMed ID: 21627828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
    Jenkins CR; Jones PW; Calverley PM; Celli B; Anderson JA; Ferguson GT; Yates JC; Willits LR; Vestbo J
    Respir Res; 2009 Jun; 10(1):59. PubMed ID: 19566934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
    Frith PA; Thompson PJ; Ratnavadivel R; Chang CL; Bremner P; Day P; Frenzel C; Kurstjens N;
    Thorax; 2015 Jun; 70(6):519-27. PubMed ID: 25841237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.
    Papi A; Dokic D; Tzimas W; Mészáros I; Olech-Cudzik A; Koroknai Z; McAulay K; Mersmann S; Dalvi PS; Overend T
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1961-1971. PubMed ID: 28740376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.
    Vestbo J; Soriano JB; Anderson JA; Calverley P; Pauwels R; Jones P;
    Respir Med; 2004 Nov; 98(11):1045-50. PubMed ID: 15526804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011.
    Betsuyaku T; Kato M; Fujimoto K; Hagan G; Kobayashi A; Hitosugi H; James M; Jones PW
    Int J Chron Obstruct Pulmon Dis; 2013; 8():453-9. PubMed ID: 24124358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
    Wedzicha JA; Calverley PM; Seemungal TA; Hagan G; Ansari Z; Stockley RA;
    Am J Respir Crit Care Med; 2008 Jan; 177(1):19-26. PubMed ID: 17916806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study.
    Paly VF; Naya I; Gunsoy NB; Driessen MT; Risebrough N; Briggs A; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():939-951. PubMed ID: 31190781
    [No Abstract]   [Full Text] [Related]  

  • 13. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
    Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse in FEV1 Decline After Steroid Withdrawal in COPD.
    Kunz LIZ; Postma DS; Klooster K; Lapperre TS; Vonk JM; Sont JK; Kerstjens HAM; Snoeck-Stroband JB; Hiemstra PS; Sterk PJ;
    Chest; 2015 Aug; 148(2):389-396. PubMed ID: 25836351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients.
    Tzani P; Crisafulli E; Nicolini G; Aiello M; Chetta A; Clini EM; Olivieri D
    Int J Chron Obstruct Pulmon Dis; 2011; 6():503-9. PubMed ID: 22069361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison.
    Boonsawat W; Goryachkina L; Jacques L; Frith L
    Clin Drug Investig; 2008; 28(2):101-11. PubMed ID: 18211118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
    Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.